5-Fluorouracil derivatives: a patent review (2012 – 2014)

Bibliography

• Ohhara Y, Suenaga M, Matsusaka S, et al. Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer. Oncol Targets Ther 2015;8:529-37
   PubMed Web of Science ®Google Scholar
• Noordhuis P, Holwerda U, Van der Wilt CL, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 2004;15(7):1025-32
   PubMed Web of Science ®Google Scholar
• Cunningham D, James RD. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. Eur J Cancer 2001;37(7):826-34
   PubMed Web of Science ®Google Scholar
• YH J. First principles calculation pka values for 5-substituted uracils. J Phys Chem A 2001;105:274-80
   Web of Science ®Google Scholar
• Zhang FM, Yao XJ, Tian X, Tu YQ. Synthesis and biological evaluation of new 4beta-5-Fu-substituted 4’-demethylepipodophyllotoxin derivatives. Molecules 2006;11(11):849-57
   PubMed Web of Science ®Google Scholar
• Xiong J, Zhu HF, Zhao YJ, et al. Synthesis and antitumor activity of amino acid ester derivatives containing 5-fluorouracil. Molecules 2009;14(9):3142-52
   PubMed Web of Science ®Google Scholar
• Jung E. Syntheses, antitumor activities, and antiangiogenesis of a monomer and its medium molecular weight polymers: maleimidoethanoyl-5-fluorouracil and its polymers. J Polym Sci 2000;38:1247-56
   Web of Science ®Google Scholar
• Lee JS, Jung YJ, Kim YM. Synthesis and evaluation of N-acyl-2-(5-fluorouracil-1-yl)-D,L-glycine as a colon-specific prodrug of 5-fluorouracil. J Pharm Sci 2001;90(11):1787-94
   PubMed Web of Science ®Google Scholar
• Daumar P, Decombat C, Chezal JM, et al. Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs. Eur J Med Chem 2011;46(7):2867-79
   PubMed Web of Science ®Google Scholar
• Pan X, Wang C, Wang F, et al. Development of 5-Fluorouracil derivatives as anticancer agents. Curr Med Chem 2011;18(29):4538-56
   PubMed Web of Science ®Google Scholar
• Cai TB, Tang X, Nagorski J, et al. Synthesis and cytotoxicity of 5-fluorouracil/diazeniumdiolate conjugates. Bioorg Med Chem 2003;11(23):4971-5
   PubMed Web of Science ®Google Scholar
• Mori M, Hatta H, Nishimoto S. Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5-fluoro-1-(2-oxocycloalkyl)uracils as a new class of radiation-activated antitumor prodrugs. J Org Chem 2000;65(15):4641-7
   PubMed Web of Science ®Google Scholar
• Dominguez JF, Marchal JA, Correa A, et al. Synthesis and evaluation of new 5-fluorouracil antitumor cell differentiating derivatives. Bioorg Med Chem 2003;11(3):315-23
   PubMed Web of Science ®Google Scholar
• Qian S, Wu JB, Wu XC, et al. Synthesis and characterization of new liver targeting 5-fluorouracil-cholic acid conjugates. Arch Pharm (Weinheim) 2009;342(9):513-20
   PubMed Web of Science ®Google Scholar
• Huang X, Xiao Y, Lang M. Self-assembly of pH-sensitive mixed micelles based on linear and star copolymers for drug delivery. J Colloid Interface Sci 2011;364(1):92-9
   PubMed Web of Science ®Google Scholar
• Gu C, Le V, Lang M, Liu J. Preparation of polysaccharide derivates chitosan-graft-poly(varepsilon-caprolactone) amphiphilic copolymer micelles for 5-fluorouracil drug delivery. Colloids Surf B Biointerfaces 2014;116:745-50
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang H, Zhou M, et al. Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. Cancer Lett 2009;279(1):30-8
   PubMed Web of Science ®Google Scholar
• Jiang H, Dong Q, Luo X, et al. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Cancer Lett 2014;342(1):113-20
   PubMed Web of Science ®Google Scholar
• Garcia MA, Carrasco E, Aguilera M, et al. The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PLoS ONE 2011;6(8):e23887
   PubMed Web of Science ®Google Scholar
• Alvarez P, Marchal JA, Boulaiz H, et al. 5-Fluorouracil derivatives: a patent review. Expert Opin Ther Patent 2012;22(2):107-23
   PubMed Web of Science ®Google Scholar
• Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer 2015;14(1):1-10
   PubMed Web of Science ®Google Scholar
• Grem JL, Nguyen D, Monahan BP, et al. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 1999;58(3):477-86
   PubMed Web of Science ®Google Scholar
• Marchal JA, Boulaiz H, Suarez I, et al. Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives. Invest New Drugs 2004;22(4):379-89
   PubMed Web of Science ®Google Scholar
• Grem JL, Yee LK, Venzon DJ, et al. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 1997;40(2):117-25
   PubMed Web of Science ®Google Scholar
• Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005;5(6):447-58
   PubMed Web of Science ®Google Scholar
• Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000;18(4):299-313
   PubMed Web of Science ®Google Scholar
• Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet 2006;45(6):567-92
   PubMed Web of Science ®Google Scholar
• Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996;77(3):441-51
   PubMed Web of Science ®Google Scholar
• Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009;101(22):1543-52
   PubMed Web of Science ®Google Scholar
• Rose A. Fluorouracil derivatives. US2013/0109707; 2013
   Google Scholar
• Gant TG. Using deuterium in drug discovery: leaving the label in the drug. J Med Chem 2014;57(9):3595-611
   PubMed Web of Science ®Google Scholar
• Sharma R, Strelevitz TJ, Gao H, et al. Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs. Drug Metab Dispos 2012;40(3):625-34
   PubMed Web of Science ®Google Scholar
• Xia G, Benmohamed R, Morimoto RI, et al. Deuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic properties. Bioorg Med Chem Lett 2014;24(21):5098-101
   PubMed Web of Science ®Google Scholar
• Soares PM, Mota JM, Souza EP, et al. Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4. Cytokine 2013;61(1):46-9
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Gross E, Dahan L, et al. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer 2010;9(4):224-8
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Okamoto H, Kawamura K, et al. The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix. Eur J Obstet Gynecol Reprod Biol 2012;163(1):67-70
   PubMed Web of Science ®Google Scholar
• Taomoto J, Yoshida K, Wada Y, et al. Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines. Oncology 2006;70(6):458-64
   PubMed Web of Science ®Google Scholar
• Fukushima M, Yamada S, Oyama R. Novel 5-fluorouracil derivative. WO2011/052554; 2011
   Google Scholar
• Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587(2-3):194-205
   PubMed Web of Science ®Google Scholar
• Christopher M. Phosphoramidate derivatives of 5 - fluoro - 2 ’ - deoxyuridine for use in the treatment of cancer. WO2012117246A1; 2012
   Google Scholar
• Malet-Martino M, Jolimaitre P, Martino R. The prodrugs of 5-fluorouracil. Curr Med Chem Anticancer Agents 2002;2(2):267-310
   PubMedGoogle Scholar
• Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19(21):4097-106
   PubMed Web of Science ®Google Scholar
• Jeon EK, Hong SH, Kim TH, et al. Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer. Cancer Res Treat 2011;43(3):148-53
   PubMedGoogle Scholar
• Castan M. Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI). WO2012146610 A1; 2012
   Google Scholar
• Sanofi. Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen. Clinical Trials.gov identifier: NCT00561470; 2012
   Google Scholar
• Faried A, Faried LS, Nakagawa T, et al. Chemically synthesized sugar-cholestanols possess a preferential anticancer activity involving promising therapeutic potential against human esophageal cancer. Cancer Sci 2007;98(9):1358-67
   PubMed Web of Science ®Google Scholar
• Yazawa S. Cholestanol derivative for combined use. US20120009251; 2012
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44
   PubMed Web of Science ®Google Scholar
• Metges JP, Lebot MA, Faroux R. Evaluation in usual practice of the bevacizumab–FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics. Oncologie 2014;16:267-76
   Web of Science ®Google Scholar
• Rotem Yehudar R. Monoclonal antibodies for tumor treatment. US20140302032A; 2014
   Google Scholar
• Rotem-Yehudar R. Variants of humanized immunomodulatory monoclonal antibodies. US8686119B2; 2014
   Google Scholar
• Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14(10):3044-51
   PubMed Web of Science ®Google Scholar
• Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241(1):27-39
   PubMed Web of Science ®Google Scholar
• Birts CN, Harding R, Soosaipillai G, et al. Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance. Biol Cell 2010;103(1):1-19
   PubMed Web of Science ®Google Scholar
• Nadauld LD, Phelps R, Moore BC, et al. Adenomatous polyposis coli control of C-terminal binding protein-1 stability regulates expression of intestinal retinol dehydrogenases. J Biol Chem 2006;281(49):37828-35
   PubMed Web of Science ®Google Scholar
• Jin W, Scotto KW, Hait WN, Yang JM. Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells. Biochem Pharmacol 2007;74(6):851-9
   PubMed Web of Science ®Google Scholar
• Gidekel M. Use of CTBP1 siRNA for the treatment of gastric cancer. US20140328944A1; 2014
   Google Scholar
• Hongxia Y, Good W, Hong H, Yan H. Containing 5-fluorouracil pharmaceutical compositions and use. CN103948688A; 2014
   Google Scholar
• Zhang WW, Zhu YJ, Yang H, et al. Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma. Sci Rep 2015;5:8071
   Web of Science ®Google Scholar
• Silvestris N, Maiello E, De Vita F, et al. Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treat Rev 2010;36(Suppl 3):S46-55
   PubMed Web of Science ®Google Scholar
• Zacharchuk CMQ, SE, Wang KY, Binlich FMH. Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine. US20140171384A1; 2014
   Google Scholar
• Bhargava P, Esteves WB. Tivozanib and temsirolimus in combination. WO2011060162A1; 2015
   Google Scholar
• Lin B. Tivozanib and capecitabine combination therapy. US20120252829A1; 2012
   Google Scholar
• Sorrentino MF. 5-Fluorouracil induced cardiotoxicity. Rev Lit 2012;19(5):453-8
   Google Scholar
• Roa B, Colvin C, Overfield M, et al. Method of assaying 5-FU. US8440442B2; 2013
   Google Scholar
• Hu P. Assays, antibodies, immunogens and other compositions related with 5-FU. WO 2013032463; 2013
   Google Scholar
• O’Neil JD, von Borstel. Determinig the severity of 5-Fluorouracil overdose. US20120078529A1; 2012
   Google Scholar
• John P. Compositions and methods for treatment of the side effects associated with administration of cancer chemotherapeutic agents. US8653090B2; 2014
   Google Scholar
• Barrueco N, Such Diaz A, Saez de la Fuente J, Escobar I. [Hyperammonemic encephalopathy in a patient treated with 5-fluorouracil]. Farm Hosp 2014;38(1):77-8
   PubMedGoogle Scholar
• Dedic Plavetic N, Rakusic Z, Ozretic D, et al. Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen. World J Surg Oncol 2014;12:264
   PubMed Web of Science ®Google Scholar
• Chu G. Assessing risk for encephalopathy induced by 5-fluorouracil or capecitabine. WO2014137705; 2014
   Google Scholar
• Cho SH. Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer (TPSHNSCC). Clinical Trials.gov identifier: NCT01645748
   Google Scholar
• Freedman R. HKI-272 for HER2-Positive Breast Cancer and Brain Metastases. ClinicalTrials.gov Identifier: NCT01494662; 2015
   Google Scholar
• Puma Biotechnology I. Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer. ClinicalTrials.gov Identifier: NCT00741260; 2015
   Google Scholar
• Puma Biotechnology I. Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer. ClinicalTrials.gov Identifier: NCT00777101; 2015
   Google Scholar
• AVEO Pharmaceuticals I. A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors. ClinicalTrials.gov Identifier: NCT01306630; 2014
   Google Scholar
• Bathini V. Trial of Chemo & Radiation Therapy for Pancreatic Cancer. ClinicalTrials.gov Identifier: NCT00424827; 2015
   Google Scholar
• Tahara M, Onozawa Y, Fujii H, et al. Feasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck. Jpn J Clin Oncol 2014;44(7):661-9
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Stohlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013;14(8):697-710
   PubMed Web of Science ®Google Scholar
• Dohme. MS. A Dose Escalation Study of MK1775 in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005). ClinicalTrials.gov Identifier: NCT01047007; 2015
   Google Scholar
• Chong Z. Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma. ClinicalTrials.gov Identifier:NCT01616849; 2015
   Google Scholar
• Peter W. Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer. ClinicalTrials.gov Identifier: NCT00068575; 2012
   Google Scholar
• TopoTarget A/S. Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors. ClinicalTrials.gov Identifier: NCT00413322; 2014
   Google Scholar
• Galectin Therapeutics Inc. GT. GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer. ClinicalTrials.gov Identifier: NCT00110721; 2012
   Google Scholar
• Galectin Therapeutics Inc. GT. Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer. ClinicalTrials.gov Identifier: NCT00386516; 2014
   Google Scholar
• Serpi M, Madela K, Pertusati F, Slusarczyk M. Synthesis of phosphoramidate prodrugs: ProTide approach. Curr Protoc Nucleic Acid Chem 2013;53:15.5.1-15.5.15
   Google Scholar
• Gonzalez-Sarrias A, Tome-Carneiro J, Bellesia A, et al. The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells. Food Funct 2015;6(5):1460-9
   Google Scholar
• Petrelli F, Coinu A, Ghilardi M, et al. Efficacy of Oxaliplatin-based Chemotherapy+Bevacizumab as First-line Treatment for Advanced Colorectal Cancer: A Systematic Review and Pooled Analysis of Published Trials. Am J Clin Oncol 2015;38(2):227-33
   PubMed Web of Science ®Google Scholar
• Conroy T. Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma. ClinicalTrials.gov Identifier: NCT01526135; 2015
   Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703
   PubMed Web of Science ®Google Scholar
• Ramanathan R. S1313, Combination Chemotherapy With or Without PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer. ClinicalTrials.gov Identifier:NCT01959139; 2015
   Google Scholar
• Vermorken JB, Stohlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013;14(8):697-710
   PubMed Web of Science ®Google Scholar
• Roussy G. Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment. ClinicalTrials.gov Identifier: NCT01566019; 2014
   Google Scholar
• Zhang XF, Li KK, Gao L, et al. miR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBPbeta. Oncotarget 2015;6(6):4144-58
   PubMedGoogle Scholar
• Kjersem JB, Ikdahl T, Lingjaerde OC, et al. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol 2014;8(1):59-67
   PubMed Web of Science ®Google Scholar
• Chen J, Wang W, Zhang Y, et al. Predicting distant metastasis and chemoresistance using plasma miRNAs. Med Oncol 2014;31(1):799
   PubMed Web of Science ®Google Scholar
• He J, Xie G, Tong J, et al. Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo. Cell Biochem Biophys 2014;70(2):1343-50
   PubMed Web of Science ®Google Scholar
• Akao Y, Khoo F, Kumazaki M, et al. Extracellular disposal of tumor-suppressor miRs-145 and -34a via microvesicles and 5-FU resistance of human colon cancer cells. Int J Mol Sci 2014;15(1):1392-401
   PubMed Web of Science ®Google Scholar
• Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 2008;13(8):1551-69
   PubMed Web of Science ®Google Scholar